Prior to the Board’s July meeting to conduct cost affordability reviews for Farxiga and Jardiance, Aimed Alliance submitted a letter…
On July 27, 2026, Aimed Alliance sent a letter to the Maryland Prescription Drug Affordability Board urging it to not…
The U.S. Trade Office has announced it is opening an investigation into Germany over its spending on prescription drugs, with…
On June 24, Aimed Alliance sent a letter to the Colorado Prescription Drug Affordability Board urging it not to establish…
The Food and Drug Administration’s (FDA) integration of artificial intelligence (AI) into drug development and manufacturing is expanding rapidly, but…
A recent Office of Inspector General (OIG) report investigating the impact of vertical integration in Medicare Part D highlights significant…
On May 19, Governor Spanberger vetoed H.B.483/S.B.271, which would have established a Prescription Drug Affordability Board (PDAB) in Virginia. Aimed…
Aimed Alliance has released a new resource explaining recent federal reforms to pharmacy benefit managers (PBMs) under the Consolidated Appropriations…
On May 19, Governor Spanberger vetoed H.B.483/S.B.271, which would have established a Prescription Drug Affordability Board (PDAB) in Virginia. Aimed…
On March 13, 2026, Aimed Alliance commented on the 2027 Notice of Benefit and Payment Parameters (2027 NBPP). In its…